Eculizumab as a Fast-Acting Therapy in a Myasthenic Crisis Patient With Poor Response to Efgartigimod
This case report hints the potential of complement inhibitors as viable treatments alternative for MC patients who poorly respond to antibody-clearing therapy. Besides, further research is necessary to determine the preferred or suitable treatment option for specific patients.
Authors
- Xinyan Guo
- Zhouyi Wang (ORCID: https://orcid.org/0009-0002-8690-247X)
- Tiancheng Luo
- Tianyu Ma
- Zhouao Zhang
- Mingjin Yang
- Yong Zhang
- Xiaoyu Huang
- Xue Du
Institutions
- Xuzhou Medical College (CN)
- Tianjin Medical University General Hospital (CN)
- Affiliated Hospital of Xuzhou Medical College (CN)
Publication Details
- Journal
- The Neurologist
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1097/nrl.0000000000000651
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00